Today we received news of an excellent report from the Canadian Cancer Research Alliance (CCRA) and the Canadian Partnership Against Cancer (CPAC). This study provides a detailed look at where cancer research money is allocated, specifically in the fields of cancer survivorship and palliative/end-of-life care.
Survivorship research is of particular interest to Kidney Cancer Canada. You might be interested in this paragraph (emphasis added):
Over half (55%) of the average annual investment in survivorship research was focused on specific cancers. For several types of cancer, the distribution of investment in research targeting a given cancer site was similar to or higher than the prevalence (patients still alive after a diagnosis of cancer) for that cancer site. For colorectal, prostate, and bladder cancers, however, the proportion of research investment fell well below the relative prevalence, and there was no investment in survivorship research focused on melanoma or kidney and pancreatic cancers.
Read the release:
In recent years, the medical community has learned a great deal about what it means to live with kidney cancer, the long-term effects of kidney surgery, and the life-time risks for kidney cancer patients. Unfortunately, not many patients have been given information or a meaningful survivorship care plan.
With over 22,000 people in Canada living with kidney cancer that was diagnosed in the past 10 years, there is increased need to study long-term survivorship. We’re not sure what that investment should look like, but we’re pretty confident that $0 isn’t enough.